Stories about Krebs

CBmed GmbH

Is microplastic carcinogenic?

Graz/Vienna (ots) - The effects of micro- and nanoplastic particles (MNP) in the human body are being investigated in depth for the first time worldwide. From 2022 to 2025, research will be performed at CBmed together with international partners to elucidate potential health effects of microplastics. Every person in developed countries currently ingests an average of five grams of plastics per week - that's as much as a standard credit card. What these micro- and nanoplastic ...

Technische Universität München

Overcoming resistance of pancreatic cancer to immunotherapies

Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37173 High resolution images: https://mediatum.ub.tum.de/1641984 NEWS RELEASE “Inflaming” cold tumors Overcoming resistance of pancreatic cancer to immunotherapies Pancreatic carcinoma is a ...

Sysmex Inostics GmbH

University of Chicago Clinical Trial Utilizes Sysmex Inostics Highly Effective HPV-SEQ Test to Measure HPV-DNA from Blood of Neck and Throat Cancer Patients

Baltimore, MD (ots) - Sysmex Inostics, a global leader in the liquid biopsy revolution for oncology, announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial,1 “Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer.” “The ability to reliably detect HPV-DNA ...

IEVA (Independent European Vape Alliance)

Vaping industry underlines the importance of product choice

Brussels (ots) - The Independent European Vape Alliance (IEVA) welcomed the decision of MEPs to recognize tobacco harm reduction as a tool in beating cancer; but remains concerned that the report approved today by the European Parliament leaves the door open to a flavour ban in the EU. The Special Committee on Beating Cancer (BECA) today voted on the amendments and the draft of the Beating Cancer report by Rapporteur ...

PM-International AG

CHRISTMAS COMES EARLY FOR CHILDREN WITH CANCER COURTESY OF PM-INTERNATIONAL MALAYSIA

Technische Universität München

New X-ray technology: Dark-field X-ray technology improves diagnosis of pulmonary ailments

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/36892 High resolution images: https://mediatum.ub.tum.de/1621886 NEWS RELEASE New X-ray technology first used with patients Dark-field X-ray technology ...

Sysmex Inostics GmbH

New Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inostics

Technische Universität München

A protein causes higher risk of severe cancer progression for men

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/36939 High resolution images: https://mediatum.ub.tum.de/1631416 NEWS RELEASE Cause found for higher sex-specific risk of mortality A protein causes significantly higher risk of severe cancer progression for men A ...

Dermago GmbH

ePresentation of the results of the in-vitro study regarding the anti-proliferative and pro-apoptotic effects of Polyphenon® E (Veregen®) at the 31st German Skin Cancer Congress on 10 September 2021

Strausberg (ots) - Aresus Pharma GmbH, a company of DERMAGO Holding GmbH, announced today that the abstract "Inhibition of cell-proliferation and cell viability by Polyphenon E ® (Veregen®) in cutaneous SCC cell lines" has been accepted as an e-poster short presentation at the 31st German Skin Cancer Congress. In ...

Fördergesellschaft IZB mbH

7

Biotech start-ups at the IZB close deals worth more than 140 million EUR in the first half of 2021

Helmholtz Zentrum München

Gastrulation research reveals novel details about embryonic development

Sysmex Inostics GmbH

Sysmex Inostics presents data at ASCO

Baltimore, MD (ots) - Sysmex Inostics presents data at ASCO showing HPV-SEQ, a new CLIA-validated SafeSEQ NGS HPV16/18 liquid biopsy assay, is highly effective for measuring HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial. Sysmex Inostics, Inc., a global leader in the liquid biopsy revolution for oncology, is presenting the poster ...

Fördergesellschaft IZB mbH

2

Lindis Biotech develops immunotherapy against bladder cancer

Sysmex Inostics GmbH

Sysmex Inostics Presents Data at AACR Demonstrating SafeSEQ NGS Liquid Biopsy Delivers Equivalent Performance to the Extensively Clinically Validated OncoBEAM dPCR Technology for NSCLC Patients

Baltimore, MD, USA (ots) - Sysmex Inostics, Inc., a global leader of the liquid biopsy revolution for oncology, is presenting the poster “Clinical evaluation of NGS-based liquid biopsy testing in non-small cell lung cancer (NSCLC) patients” at the 112th Annual Meeting of the American Association for Cancer ...

Universität Mannheim

Social Stigma Burdens Innovative Lung Cancer-Therapies, Study Says

Social Stigma Burdens Innovative Lung Cancer-Therapies, Study Says Social stigma towards diseases such as lung cancer can hinder patients to seek treatment and, as a consequence, negatively affects the diffusion of innovative therapies, according to a recently published study. “Lung cancer carries a unique social stigma due to its association with cigarette smoking, and hence is often seen as a smoker’s disease, ...

European Society for Medical Oncology (ESMO)

Launch of ESMO Virtual Plenaries Brings Rapid Access to Ground-Breaking Cancer Research

IEVA (Independent European Vape Alliance)

Beating cancer with Harm Reduction

Bruxelles (ots) - The Independent European Vape Alliance (IEVA) welcomes and supports the “EU Beating Cancer Plan” presented today by the European Commission. The plan is extremely important in order to significantly reduce the number of cancer-related deaths. However, the new EU strategy neglects an important instrument for public health: Harm Reduction. Almost one third of cancer cases in Europe are caused by smoking: “Tobacco consumption continues to be the leading ...

Fördergesellschaft IZB mbH

3

World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools

Technische Universität München

Sixfold increase in risk: study shows link between cervical cancer and HIV infection

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36390/ High resolution images: https://mediatum.ub.tum.de/1585216 NEWS RELEASE Sixfold increase in risk Link between cervical cancer and HIV infection A ...

Sysmex Inostics GmbH

Sysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity of SafeSEQ NGS Technology for Detection of Measurable Residual Disease in Acute Myeloid Leukemia

Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based, high-sensitivity molecular testing for oncology, is presenting the poster "Ultrasensitive Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML) Using a Targeted Next Generation Sequencing (NGS) Panel" at ...

Helmholtz Zentrum München

4

Novel medical imaging approach unlocks potential for improved diagnosis and interventions

Sysmex Inostics GmbH

Sysmex Inostics' Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management

Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating cell-free tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study investigating the utility of cfDNA-based markers using the highly sensitive OncoBEAM RAS assay, an enhanced ...

Sysmex Inostics GmbH

Sysmex Inostics' OncoBEAMTM RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy

Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating RAS mutation status in circulating tumor DNA (ctDNA) of colorectal cancer (CRC) patients undergoing anti-EGFR ...

Carl Zeiss Meditec AG

Effectiveness and efficiency of targeted intra-operative single dose radiotherapy for breast cancer patients confirmed

Jena, Germany (ots) - New long-term results from the international TARGIT-A breast cancer study, based on ZEISS technology, have been published [1] Use of targeted intra-operative radiotherapy (TARGIT), as a single dose - with ZEISS INTRABEAM - directly after removal of a tumor, confirmed as non-inferior, when ...

Sysmex Inostics GmbH

Sysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing

Baltimore, Maryland (ots) - Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of plasma RAS mutation testing with OncoBEAM RAS CRC as compared to standard of care ...

Helmholtz Zentrum München

AI & single-cell genomics: New software predicts cell fate

Technische Universität München

Improving immunotherapy for cancer

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161/ 71-5403 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36023/ High resolution images: https://mediatum.ub.tum.de/1544218 NEWS RELEASE Cause for the lack of immune defense against tumors discovered Improving immunotherapy for cancer One of the reasons why cancer develops is because regulatory cells inhibit the body's ...

Sysmex Inostics GmbH

Sysmex Inostics' updated SafeSEQ Breast Cancer Panel advances novel clinical uses of ctDNA through quantitative testing

Baltimore, Maryland (ots) - Building on the ultra-high sensitivity SafeSEQ Breast Cancer Panel circulating tumor DNA (ctDNA) test launched at the American Association of Cancer Research 2019 annual meeting, Sysmex Inostics has updated the test to provide additional key information for investigation of the validity ...

Spectrum. The most dangerous artwork

On February 4 is World Cancer Day. German Cancer Aid and Dermatological Prevention Association demand: Sunbed Ban

Sysmex Inostics GmbH

Sysmex Inostics and Oxford Gene Technology plasma and tissue sequencing show clearance of ctDNA correlates with pathologic complete response in breast cancer patients during neoadjuvant treatment

Hamburg, Germany and Baltimore, Maryland (ots) - Pathologist Dr. Vincente Peg of the Vall d´Hebron University Hospital (Barcelona Spain) and colleagues have presented a correlation between the clearance of circulating tumor DNA (ctDNA) in HER2-positive or triple-negative breast cancer patients undergoing ...